Substance P receptor antagonists in the therapy of migraine

Expert Opinion on Investigational Drugs

Volumn 10, Issue 4, 2001, Pages 673-678

  May, A ^a   Goadsby, P J ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Migraine attack; Neurogenic inflammation; Plasma extravasation; Substance P; Trigeminovascular system

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; BOSENTAN; CALCITONIN GENE RELATED PEPTIDE; ENDOTHELIN RECEPTOR ANTAGONIST; LANEPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 1 AGONIST; SUBSTANCE P; SUBSTANCE P ANTAGONIST; VOFOPITANT;

ANIMAL MODEL; BLOOD VESSEL; CLINICAL OBSERVATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DURA MATER; HUMAN; INNERVATION; MIGRAINE; NEUROGENIC INFLAMMATION; NONHUMAN; PAIN; REVIEW; TRIGEMINAL NERVE; VASOCONSTRICTION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MIGRAINE DISORDERS; RECEPTORS, NEUROKININ-1;

EID: 0035074009     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.4.673     Document Type: Review

References (72)

1. The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist
2. Recent developments in tachykinin NK1 receptor antagonists: Prospects for the treatment of migraine headache
3. Selective blockade of substance P or neurokinin A receptors reduces the expression of c-fos in trigeminal subnucleus caudalis after corneal stimulation in the rat
4. Role of endothelin in mediating neurogenic plasma extravasation in rat dura mater
5. Dihydroergotamine and Sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion
6. The anti-migraine drug sumatriptan (GR 43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater
7. The trigemino-vascular system and migraine
8. Further characterisation of the 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater
9. Lack of a role for substance P in the control of dural arterial flow
10. Attenuation of Fos-like immunoreactivity in the trigeminal nucleus caudalis following trigeminovascular activation in the anaesthetised guinea-pig
11. Clinical evaluation of a novel, potent, CNS penetrating NK1 receptor antagonist in the acute treatment of migraine
12. Naratriptan: Biological profile in animal models relevant to migraine
13. Effect of sumatriptan on sensory neurotransmission in guinea-pig basilar artery
14. The mechanisms and treatment of migraine
15. A study of safety and efficacy in patients with acute migraine, using PNU-142633, a selective 5-HT1D agonist
16. The non-peptide neurokinin-1 antagonist, RPR 100893, decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation
17. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P
18. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery
19. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain
20. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro
21. Neuropeptides in the cerebral circulation: Relevance to headache
22. Increases in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack
23. Presynaptic inhibitory action of 5HT in dog isolated saphenous vein
24. Transmitters involved in antinociception in the spinal cord
25. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
26. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies
27. Neuropeptide changes in a case of chronic paroxysmal hemicrani-aevidence for trigemino-parasympathetic activation
28. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigemino-vascular system
29. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
30. Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation
31. Ineffectiveness of neurokinin-1 antagonist in acute migraine: A crossover study
32. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist
33. 1D-like receptor
34. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism
35. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption
36. Blockade by oral or parenteral RPR 100893 (a non-peptide NK1 receptor antagonist) of neurogenic plasma protein extravasation within guinea- pig dura mater and conjunctiva
37. R91274 (alniditan) blocks neurogenic inflammation in the rat meninges more effectively than sumatriptan by activation of 5HT1D-receptors
38. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain
39. Neurogenically mediated plasma extravasation in dura mater: Effect of ergot alkaloids. A possible mechanism of action in vascular headache
40. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
41. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks
42. The trigeminovascular system in humans: Pathophysiological implications for primary headache syndromes of the neural influences of the cerebral circulation
43. Retinal plasma extravasation in animals but not in humans: Implications for the pathophysiology of migraine
44. Release of immunoreactive substance P in the brain stem upon stimulation of the cranial dura mater with low pH - Inhibition by the serotonin (5-HT1) receptor agonist CP 93,129
45. The neurobiology of vascular head pain
46. Neurogenic versus vascular mechanisms of sumatriptan and ergot alcaloids in migraine
47. Neurogenic inflammation in the pathophysiology and treatment of migraine
48. In vitro release of immunoreactive substance P from putative afferent nerve endings in bovine pia arachnoid
49. Intracerebral arteries and gadolinium enhancement in migraine without aura
50. A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intravenous L-758,298 ( a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine
51. Investigation of the role of tachykinin NK1, NK2 receptors and CGRP receptors in neurogenic plasma protein extravasation in dura mater
52. Localization of serotonin- and substance P-like immunofluorescence in the caudal spinal trigeminal nucleus of the rat
53. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs
54. The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system
55. The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation
56. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles
57. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache
58. Migraine and cutaneous vessels
59. Ergot alkaloids block neurogenic extravasation in dura mater: Proposed action in vascular headaches
60. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion
61. The tachykinin NK1 receptor in the brain: Pharmacology and putative functions
62. The non-peptide neurokinin-1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats
63. Comparison of the effects of sumatriptan and the NK-1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos RNA expression in trigeminal nucleus caudalis of rats
64. Response of brainstem trigeminal neurons to electrical stimulation of the dura
65. Sensitization of meningeal sensory neurons and the origin of headaches
66. Central neurogenic mechanisms of migraine
67. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilatation and extravasation
68. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides